mitochondria protein modules

Byaibio

Mitochondria are energy-producing organelles that also regulate calcium handling, redox balance, apoptosis, and innate immune signaling, and this entry focuses on protein modules linked to mitochondrial function. In Alzheimer’s disease, these modules were decreased in asymptomatic AD and AD cases versus controls, consistent with mitochondrial dysfunction as an early disease feature and with the Key Facts note that they are decreased in AsymAD and AD. They are also implicated in chemotherapy-related hematopoietic protection, where dietary restriction improves mitochondrial homeostasis and activation in hematopoietic stem/progenitor cells to mitigate 5-fluorouracil-induced thrombocytopenia. Beyond disease association, mitochondria are a therapeutic target for mitochondrial GSH depletion, ROS amplification, mitochondrial DNA release, and mitochondrial transplantation, including delivery of viable, respiratory-competent organelles to injured tissue. Recent studies also highlight mitochondria in cuproptosis, endothelial-cell transfer, and neurodegeneration, underscoring their role as both a disease hub and a druggable organelle.

Neurodegeneration

  • Mitochondria-related protein modules were decreased in asymptomatic AD and AD cases compared with controls, supporting early mitochondrial involvement in Alzheimer’s disease (PMID:41922169).
  • A 2026 Analytical Chemistry study (PMID:42003377) described near-infrared carbon dots that selectively target and protect mitochondria in an Alzheimer’s disease pathological cascade.
  • A 2026 Neural Regeneration Research review (PMID:41975595) highlighted mitochondria as calcium-storing organelles and druggable targets in neurodegenerative diseases.
  • Mitochondrial dysfunction and mitochondrial Ca2+ handling were discussed as therapeutic targets in Parkinson’s disease (PMID: not provided in Papers; relation only).

Hematopoiesis and thrombocytopenia

  • Dietary restriction improved mitochondrial homeostasis and activation in hematopoietic stem/progenitor cells, helping protect against 5-fluorouracil-induced thrombocytopenia (PMID:41932340).
  • The same study linked mitochondrial potentiation in hematopoietic stem cells and megakaryocyte progenitors to reduced thrombocytopenia in aged mice (PMID:41932340).
  • Targeting mitochondria was proposed as a novel therapeutic strategy for chemotherapy-induced thrombocytopenia (PMID:41932340).

Cancer and regulated cell death

  • A 2026 European Journal of Medicinal Chemistry study (PMID:41785829) reported HsClpP activators that induced structural and functional mitochondrial impairment in multiple myeloma therapy.
  • Cuproptosis was described as a mitochondria-centered mode of regulated cell death, linking mitochondrial collapse to cancer vulnerability (PMID:41692172).
  • An Ir(III) complex with mitochondria-targeting properties depleted mitochondrial GSH and amplified photodynamic therapy via localized ROS accumulation (PMID:41941352).
  • A hydrogen-releasing nanozyme reduced mitochondrial ROS and reprogrammed mitochondria into endogenous ROS generators for self-sustaining catalytic immunotherapy (PMID:41961470).

Mitochondrial transfer, transplantation, and vascular biology

  • Mitochondria can be delivered by intra-arterial injection and rapidly integrated into target cells through endocytosis (PMID:41981250).
  • A 2026 Nature Reviews Nephrology article (PMID:41981250) emphasized mitochondrial transplantation using viable, respiratory-competent mitochondria from autologous or allogeneic sources.
  • A 2026 Circulation Research review (PMID:41955325) described mitochondrial transfer to endothelial cells as a mechanism shaping vascular health.
  • Extracellular mitochondria were also discussed as circulating entities and therapeutic transplant targets, with platelets identified as the principal source of circulating mitochondria (PMID:41955328).